D-0730-2021 Class II Terminated

Recalled by Teva Pharmaceuticals USA — Parsippany, NJ

FDA drug recall D-0730-2021 was initiated by Teva Pharmaceuticals USA on Jul 29, 2021 and is designated Class II. Reason for recall: Lack of Assurance of Sterility The recall status is terminated (terminated Jun 4, 2024). Affected quantity: 1,351 vials.

Recall details

Product Type
Drugs
Report Date
Aug 25, 2021
Initiation Date
Jul 29, 2021
Termination Date
Jun 4, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1,351 vials

Product description

DAUNOrubicin Hydrochloride Injection 20 mg/4mL, 4mL Single Dose vials, 10 in 1 carton, Rx only, Teva Parenteral Medicines, Inc. Irvine, CA 92618 Vial NDC# 0703-5233-11, Carton NDC # 0703-5233-13

Reason for recall

Lack of Assurance of Sterility

Distribution pattern

Product was distributed Nationwide, including Puerto Rico.

Code information

Lot #: 31329250B, exp. date 08/2022

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0730-2021
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0730-2021. Report a data issue: hello@regdatalab.com.